Prophylactic surgery in carriers of BRCA1 or BRCA2 gene mutation
- Authors: Gorodnova T.V1, Sokolenko A.P1, Kotiv K.B1, Yakovleva M.G1, Lavrinovich O.E1, Mikaya N.A1, Ibragimov Z.N1, Trifanov Y.N1, Bondarev N.E1, Nekrasova E.A1, Sidoruk A.A1, Smirnova O.A1, Guseinov K.D1,2, Bakhidze E.V1,2, Meshkova I.E1, Bakaeva E.K.1,2, Shikhzadaeva M.G1, Ul’rikh E.A1,2, Urmancheeva A.F1,2, Berlev I.V1,2, Imyanitov E.N1, Belyaev A.M1,2
-
Affiliations:
- N.N.Petrov Research Institute of Oncology
- I.I. Mechnikov North-Western State Medical University
- Issue: No 1S (2020): Supplement
- Pages: 56-62
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/248769
- DOI: https://doi.org/10.18565/aig.2020.1pril.56-62
- ID: 248769
Cite item
Abstract
Keywords
Full Text
About the authors
T. V Gorodnova
N.N.Petrov Research Institute of Oncology
A. P Sokolenko
N.N.Petrov Research Institute of Oncology
Email: annasoko-lenko@mail.ru
Kh. B Kotiv
N.N.Petrov Research Institute of Oncology
Email: xristinabogdanovna@gmail.com
M. G Yakovleva
N.N.Petrov Research Institute of Oncology
Email: mersend@mail.ru
O. E Lavrinovich
N.N.Petrov Research Institute of Oncology
Email: olgalav1973@mail.ru
N. A Mikaya
N.N.Petrov Research Institute of Oncology
Email: nmikaya@mail.ru
Z. N Ibragimov
N.N.Petrov Research Institute of Oncology
Email: oncl@rion.spb.ru
Yu. N Trifanov
N.N.Petrov Research Institute of Oncology
Email: oncl@rion.spb.ru
N. E Bondarev
N.N.Petrov Research Institute of Oncology
Email: oncl@rion.spb.ru
E. A Nekrasova
N.N.Petrov Research Institute of Oncology
Email: ekaterina_neks@mail.ru
A. A Sidoruk
N.N.Petrov Research Institute of Oncology
Email: sidoruk_ann@mail.ru
O. A Smirnova
N.N.Petrov Research Institute of Oncology
Email: ssmirnova.oa@gmail.com
K. D Guseinov
N.N.Petrov Research Institute of Oncology; I.I. Mechnikov North-Western State Medical University
Email: oncl@rion.spb.ru
E. V Bakhidze
N.N.Petrov Research Institute of Oncology; I.I. Mechnikov North-Western State Medical University
Email: oncl@rion.spb.ru
I. E Meshkova
N.N.Petrov Research Institute of Oncology
Email: meshkova.62@bk.ru
E. Kh Bakaeva
N.N.Petrov Research Institute of Oncology; I.I. Mechnikov North-Western State Medical University
Email: oncl@rion.spb.ru
M. G Shikhzadaeva
N.N.Petrov Research Institute of Oncology
Email: oncl@rion.spb.ru
E. A Ul’rikh
N.N.Petrov Research Institute of Oncology; I.I. Mechnikov North-Western State Medical University
Email: elenaulrikh@yandex.ru
A. F Urmancheeva
N.N.Petrov Research Institute of Oncology; I.I. Mechnikov North-Western State Medical University
Email: adaurm@mail.ru
I. V Berlev
N.N.Petrov Research Institute of Oncology; I.I. Mechnikov North-Western State Medical University
Email: iberlev@gmail.com
E. N Imyanitov
N.N.Petrov Research Institute of Oncology
Email: evgeny@imyanitov.spb.ru
A. M Belyaev
N.N.Petrov Research Institute of Oncology; I.I. Mechnikov North-Western State Medical University
Email: oncl@rion.spb.ru
References
- Alsop K., Fereday S., Meldrum C., et al. BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. JCO. 2012; 30: 2654-63. doi: 10.1200/Jm.2011.39.8545
- Gorodnova T.V., Sokolenko A.P., Ivantsov A.O., et al. High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation. Cancer Lett. 2015; 2: 363-7. doi: 10.1016/j. canlet.2015.08.028
- Ingham S.L., Sperrin M., Baildam A., et al. Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. Breast Cancer Res Treat. 2013; 3: 611-8. doi: 10.1007/s10549-013-2765-x.
- Nelson H.D., Pappas M., Zakher B., et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2014; 4: 255-66. doi: 10.7326/M13-1684
- Rice M.S., Murphy M.A., Tworoger S.S. Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis. J. Ovarian Res. 2012; 5(1): 2415-21. http://dx.doi. org/10.1186/1757-2215-5-13
- Kotsopoulos J., Huzarski T., Gronwald J., et al. Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2016; 109(1): 255-66. doi: 10.1093/jnci/djw177
- Suspitsin E.N., Sherina N.Y., Ponomariova D.N., et al. High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients. Hered Cancer Clin Pract. 2009; 7(1): 5. doi: 10.1186/1897-4287-7-5
- Domchek S.M., Friebel T.M., Singer C.F., et al. Association of risk-reducing surgery in BRCA1 or BRCA2mutation carriers with cancer risk and mortality. JAMA. 2010; 9: 967-75. doi: 10.1001/jama.2010.1237
- Medeiros F., Muto M.G., Lee Y., et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006; 30(2): 230-6. doi: 10.1097/01.pas.0000180854.28831.77
- Labidi-Galy S.I., Papp E., Hallberg D. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017; 8(1): 1093. doi:10.1038/ s41467-017-00962-1
- Marquez R.T., Baggerly K.A., Patterson A.P., et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005;11(17): 6116 26. doi: 10.1158/1078-0432.CCR-04-2509
- Ducie J., Dao F., Considine M., et al. Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nat Commun. 2017; 8(1): 990. doi: 10.1038/s41467-017-01217-9
- Mehra K.K., Chang M.C., Folkins A.K., et al. The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls. Mod Pathol. 2011; 24(1): 152-6. doi: 10.1038/modpathol.2010.171.
- Anderson C.K., Wallace S., Guiahi M., Sheeder J., Behbakht K., Spillman M.A. Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer. Int J Gynecol Cancer. 2013; 23(1): 417-21. doi: 10.1097/IGC.0b013e3182849dba
- Nebgen D.R., Hurteau J., Holman L.L., Bradford A., Munsell M.F., Soletsky B.R., et al. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: a pilot study in women with BRCA1/2 mutations. Gynecol Oncol. 2019; 20: 117-20. doi: 10.1016/j.ygyno.2018.04.564